Hypersexuality as a neuropsychiatric disorder

The neurobiology and treatment options

Muna Asiff, Hatta Sidi, Ruziana Masiran, Jaya Kumar, Srijit Das, Nurul Hazwani Hatta, Cesar Alfonso

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Hypersexuality refers to abnormally increased or extreme involvement in any sexual activity. It is clinically challenging, presents trans-diagnostically and there is extensive medical literature addressing the nosology, pathogenesis and neuropsychiatric aspects in this clinical syndrome. Classification includes deviant behaviours, diagnosable entities related to impulsivity, and obsessional phenomena. Some clinicians view an increase in sexual desire as ‘normal’ i.e. psychodynamic theorists consider it as ego-defensive at times alleviating unconscious anxiety rooted in intrapsychic conflicts. We highlight hypersexuality as multi-dimensional involving an increase in sexual activity that is associated with distress and functional impairment. The aetiology of hypersexuality is multi-factorial with differential diagnoses that include major psychiatric disorders (e.g. bipolar disorder), adverse effects of treatments (e.g. levodopa-treatment), substance-induced disorders (e.g. amphetamine substance use), neuropathological disorders (e.g. frontal lobe syndrome), among others. Numerous neurotransmitters are implicated in its pathogenesis, with dopamine and noradrenaline playing a crucial role in the neural reward pathways and emotion-ally-regulated limbic system neural circuits. The management of hypersexuality is determined by the principle of de causa effectu evanescent, if the causes are treated, the effect may disappear. We aim to review the role of pharmacological agents causing hypersexuality and centrally acting agents treating the associated underlying medical conditions. Bio-psycho-social determinants are pivotal in embracing the understanding and guiding management of this complex and multi-determined clinical syndrome.

Original languageEnglish
Pages (from-to)1391-1401
Number of pages11
JournalCurrent Drug Targets
Volume19
Issue number12
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Neurobiology
Sexual Behavior
Levodopa
Amphetamine
Neurotransmitter Agents
Neural Pathways
Dopamine
Limbic System
Norepinephrine
Ego
Impulsive Behavior
Frontal Lobe
Reward
Bipolar Disorder
Substance-Related Disorders
Psychiatry
Networks (circuits)
Emotions
Differential Diagnosis
Therapeutics

Keywords

  • Bio psychological treatment
  • Hypersexuality
  • Libido
  • Neurobiology
  • Neuropsychiatry
  • Normality

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Hypersexuality as a neuropsychiatric disorder : The neurobiology and treatment options. / Asiff, Muna; Sidi, Hatta; Masiran, Ruziana; Kumar, Jaya; Das, Srijit; Hatta, Nurul Hazwani; Alfonso, Cesar.

In: Current Drug Targets, Vol. 19, No. 12, 01.01.2018, p. 1391-1401.

Research output: Contribution to journalReview article

Asiff, Muna ; Sidi, Hatta ; Masiran, Ruziana ; Kumar, Jaya ; Das, Srijit ; Hatta, Nurul Hazwani ; Alfonso, Cesar. / Hypersexuality as a neuropsychiatric disorder : The neurobiology and treatment options. In: Current Drug Targets. 2018 ; Vol. 19, No. 12. pp. 1391-1401.
@article{bacd2a61e17747d084e036acf505568a,
title = "Hypersexuality as a neuropsychiatric disorder: The neurobiology and treatment options",
abstract = "Hypersexuality refers to abnormally increased or extreme involvement in any sexual activity. It is clinically challenging, presents trans-diagnostically and there is extensive medical literature addressing the nosology, pathogenesis and neuropsychiatric aspects in this clinical syndrome. Classification includes deviant behaviours, diagnosable entities related to impulsivity, and obsessional phenomena. Some clinicians view an increase in sexual desire as ‘normal’ i.e. psychodynamic theorists consider it as ego-defensive at times alleviating unconscious anxiety rooted in intrapsychic conflicts. We highlight hypersexuality as multi-dimensional involving an increase in sexual activity that is associated with distress and functional impairment. The aetiology of hypersexuality is multi-factorial with differential diagnoses that include major psychiatric disorders (e.g. bipolar disorder), adverse effects of treatments (e.g. levodopa-treatment), substance-induced disorders (e.g. amphetamine substance use), neuropathological disorders (e.g. frontal lobe syndrome), among others. Numerous neurotransmitters are implicated in its pathogenesis, with dopamine and noradrenaline playing a crucial role in the neural reward pathways and emotion-ally-regulated limbic system neural circuits. The management of hypersexuality is determined by the principle of de causa effectu evanescent, if the causes are treated, the effect may disappear. We aim to review the role of pharmacological agents causing hypersexuality and centrally acting agents treating the associated underlying medical conditions. Bio-psycho-social determinants are pivotal in embracing the understanding and guiding management of this complex and multi-determined clinical syndrome.",
keywords = "Bio psychological treatment, Hypersexuality, Libido, Neurobiology, Neuropsychiatry, Normality",
author = "Muna Asiff and Hatta Sidi and Ruziana Masiran and Jaya Kumar and Srijit Das and Hatta, {Nurul Hazwani} and Cesar Alfonso",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1389450118666170321144931",
language = "English",
volume = "19",
pages = "1391--1401",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Hypersexuality as a neuropsychiatric disorder

T2 - The neurobiology and treatment options

AU - Asiff, Muna

AU - Sidi, Hatta

AU - Masiran, Ruziana

AU - Kumar, Jaya

AU - Das, Srijit

AU - Hatta, Nurul Hazwani

AU - Alfonso, Cesar

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Hypersexuality refers to abnormally increased or extreme involvement in any sexual activity. It is clinically challenging, presents trans-diagnostically and there is extensive medical literature addressing the nosology, pathogenesis and neuropsychiatric aspects in this clinical syndrome. Classification includes deviant behaviours, diagnosable entities related to impulsivity, and obsessional phenomena. Some clinicians view an increase in sexual desire as ‘normal’ i.e. psychodynamic theorists consider it as ego-defensive at times alleviating unconscious anxiety rooted in intrapsychic conflicts. We highlight hypersexuality as multi-dimensional involving an increase in sexual activity that is associated with distress and functional impairment. The aetiology of hypersexuality is multi-factorial with differential diagnoses that include major psychiatric disorders (e.g. bipolar disorder), adverse effects of treatments (e.g. levodopa-treatment), substance-induced disorders (e.g. amphetamine substance use), neuropathological disorders (e.g. frontal lobe syndrome), among others. Numerous neurotransmitters are implicated in its pathogenesis, with dopamine and noradrenaline playing a crucial role in the neural reward pathways and emotion-ally-regulated limbic system neural circuits. The management of hypersexuality is determined by the principle of de causa effectu evanescent, if the causes are treated, the effect may disappear. We aim to review the role of pharmacological agents causing hypersexuality and centrally acting agents treating the associated underlying medical conditions. Bio-psycho-social determinants are pivotal in embracing the understanding and guiding management of this complex and multi-determined clinical syndrome.

AB - Hypersexuality refers to abnormally increased or extreme involvement in any sexual activity. It is clinically challenging, presents trans-diagnostically and there is extensive medical literature addressing the nosology, pathogenesis and neuropsychiatric aspects in this clinical syndrome. Classification includes deviant behaviours, diagnosable entities related to impulsivity, and obsessional phenomena. Some clinicians view an increase in sexual desire as ‘normal’ i.e. psychodynamic theorists consider it as ego-defensive at times alleviating unconscious anxiety rooted in intrapsychic conflicts. We highlight hypersexuality as multi-dimensional involving an increase in sexual activity that is associated with distress and functional impairment. The aetiology of hypersexuality is multi-factorial with differential diagnoses that include major psychiatric disorders (e.g. bipolar disorder), adverse effects of treatments (e.g. levodopa-treatment), substance-induced disorders (e.g. amphetamine substance use), neuropathological disorders (e.g. frontal lobe syndrome), among others. Numerous neurotransmitters are implicated in its pathogenesis, with dopamine and noradrenaline playing a crucial role in the neural reward pathways and emotion-ally-regulated limbic system neural circuits. The management of hypersexuality is determined by the principle of de causa effectu evanescent, if the causes are treated, the effect may disappear. We aim to review the role of pharmacological agents causing hypersexuality and centrally acting agents treating the associated underlying medical conditions. Bio-psycho-social determinants are pivotal in embracing the understanding and guiding management of this complex and multi-determined clinical syndrome.

KW - Bio psychological treatment

KW - Hypersexuality

KW - Libido

KW - Neurobiology

KW - Neuropsychiatry

KW - Normality

UR - http://www.scopus.com/inward/record.url?scp=85052208238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052208238&partnerID=8YFLogxK

U2 - 10.2174/1389450118666170321144931

DO - 10.2174/1389450118666170321144931

M3 - Review article

VL - 19

SP - 1391

EP - 1401

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -